Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Study on the combination of two immunotherapeutic agents as pre-surgical therapy or definitive treatment in patients with resectable gastric… Ended

2024-518842-26-00 Cancer in the stomach or in the junction between the st 4 2025-01-21
Infusion of ex vivo-generated allogeneic natural killer cells in combination with subcutaneous IL-2 in patients with acute myeloid leukemia:… Ended

2024-515357-16-00 MDS with excess blasts, MDS/AML or AML patients 4 2025-01-20
A trial to learn how well AZD0901 works and how safe it is compared to standard cancer treatments in adults with advanced and metastatic gas… Ended

2023-508276-11-00 Gastric cancer, Advanced/Metastatic Gastric cancer, Gas 5 2025-01-17
An open label, single-arm, phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patien… Ended

2023-504420-26-00 Bladder Cancer 4 2025-01-13
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II… Ended

2024-516530-36-00 low-grade serous carcinoma of the ovary or peritoneum 5 2025-01-08
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemother… Ended

2024-511957-23-00 Recurrent or Persistent Endometrial Cancer 5 2025-01-03
Research study on the use of capivasertib together with fulvestrant in patients with advanced breast cancer who have relapsed/progressed to … Ended

2024-513952-13-00 HR+ / HER2- advanced breast cancer 5 2025-01-02
Study to evaluate the use of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line t… Ended

2024-514728-17-00 Advanced or recurrent endometrial cancer 11 2024-12-30
Study of EGF816 in combination with selected targeted agents in EGFR-mutant NSCLC. Ended

2024-511757-21-00 Patients with EGFR-mutant Non Small Cell Lung Cancer 3 2024-12-20
A Phase 1b Study of JNJ-80948543 in Combination with Other CD3 TCEs for R/R B-cell NHL Ended

2024-514176-41-00 Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Maligna 3 2024-12-16
Preemptive treatment with venetoclax plus azacitidine in patients diagnosed with acute myeloid leukemia (AML) with persistence or reappearan… Ended

2024-510648-29-00 Patients diagnosed with acute myeloid leukemia (AML) wi 10 2024-12-12
A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL C… Ended

2024-514032-25-00 Patients with a histilogically confirmed diagnosis of c 4 2024-12-11
CompARE: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk orophar… Ended

2024-516108-41-00 Oropharyngeal cancer 5 2024-12-09
The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with… Ended

2024-511616-24-00 Relapsed and/or Refractory B-cell Lymphoma 1 2024-12-06
ICC APL STUDY 02 Treatment study for children and adolescents with Acute Promyelocytic Leukemia Ended

2024-518669-83-00 acute promyelocytic leukemia (APL) in children and adol 4 2024-12-05
Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in resected high risk colon cancer patients. - The PIPAC-OPC3 CC trial Ended

2024-519189-31-00 Colon cancer 4 2024-12-04
An open-label, multi-center, phase 2 study of chemo-immunotherapy followed by reduced-dose hypofractionated RT and maintenance immunotherapy… Ended

2024-518408-32-00 Non Small Cell Lung Cancer 4 2024-12-03
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 W… Ended

2023-505110-14-00 Colorectal Cancer 4 2024-12-02
PErsonalized TREatment of high-risk MAmmary Cancer - the PETREMAC trial Ended

2024-519364-40-00 Breast cancer 4 2024-11-29
L19IL2/L19TNF in skin cancer patients Ended

2024-518531-10-00 Phase II, open label, multicentric, proof-of-principle 4 2024-11-26
Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors. Ended

2024-513281-19-00 Nasopharyngeal Carcinoma 1 2024-11-25
NEOadjuvant Abemaciclib and GIredestrant triaL in patients with ER-positive, HER2-negative Early breast cancer Ended

2023-510153-42-00 ER-positive, HER2-negative Early breast cancer 4 2024-11-25
Study of SKB264 to treat participants with advanced non-small cell lung cancer alone or as a combination treatment Ended

2023-507270-41-00 Advanced or Metastatic Non-small Cell Lung Cancer 4 2024-11-22
Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph… Ended

2023-505989-29-00 Extensive stage small cell lung cancer (ES-SCLC) 5 2024-11-21